These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 32591942)
1. Serotonin transporter gene and escitalopram: depressing medical science. Braillon A Eur J Clin Pharmacol; 2020 Nov; 76(11):1621-1622. PubMed ID: 32591942 [No Abstract] [Full Text] [Related]
2. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960 [TBL] [Abstract][Full Text] [Related]
3. [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine]. Owens JM; Knight DL; Nemeroff CB Encephale; 2002; 28(4):350-5. PubMed ID: 12232544 [TBL] [Abstract][Full Text] [Related]
4. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Zhong H; Haddjeri N; Sánchez C Psychopharmacology (Berl); 2012 Jan; 219(1):1-13. PubMed ID: 21901317 [TBL] [Abstract][Full Text] [Related]
5. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580 [TBL] [Abstract][Full Text] [Related]
6. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Owens MJ; Knight DL; Nemeroff CB Biol Psychiatry; 2001 Sep; 50(5):345-50. PubMed ID: 11543737 [TBL] [Abstract][Full Text] [Related]
7. The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse. Jacobsen JP; Plenge P; Sachs BD; Pehrson AL; Cajina M; Du Y; Roberts W; Rudder ML; Dalvi P; Robinson TJ; O'Neill SP; Khoo KS; Morillo CS; Zhang X; Caron MG Psychopharmacology (Berl); 2014 Dec; 231(23):4527-40. PubMed ID: 24810106 [TBL] [Abstract][Full Text] [Related]
8. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Sánchez C Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):91-5. PubMed ID: 16918708 [TBL] [Abstract][Full Text] [Related]
9. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter]. Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789 [TBL] [Abstract][Full Text] [Related]
10. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Chen F; Larsen MB; Sánchez C; Wiborg O Eur Neuropsychopharmacol; 2005 Mar; 15(2):193-8. PubMed ID: 15695064 [TBL] [Abstract][Full Text] [Related]
11. Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation. Damsbo AG; Kraglund KL; Buttenschøn HN; Johnsen SP; Andersen G; Mortensen JK Cerebrovasc Dis; 2019; 47(1-2):72-79. PubMed ID: 30844812 [TBL] [Abstract][Full Text] [Related]
12. Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique. Rausch JL; Corley KM; Hobby HM J Clin Psychopharmacol; 2004 Apr; 24(2):209-13. PubMed ID: 15206668 [TBL] [Abstract][Full Text] [Related]
13. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Klein N; Sacher J; Geiss-Granadia T; Mossaheb N; Attarbaschi T; Lanzenberger R; Spindelegger C; Holik A; Asenbaum S; Dudczak R; Tauscher J; Kasper S Psychopharmacology (Berl); 2007 Apr; 191(2):333-9. PubMed ID: 17235610 [TBL] [Abstract][Full Text] [Related]
14. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Klein N; Sacher J; Geiss-Granadia T; Attarbaschi T; Mossaheb N; Lanzenberger R; Pötzi C; Holik A; Spindelegger C; Asenbaum S; Dudczak R; Tauscher J; Kasper S Psychopharmacology (Berl); 2006 Oct; 188(3):263-72. PubMed ID: 16955282 [TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with escitalopram but not R-citalopram translocates Galpha(s) from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound. Zhang L; Rasenick MM J Pharmacol Exp Ther; 2010 Mar; 332(3):977-84. PubMed ID: 19996298 [TBL] [Abstract][Full Text] [Related]
19. An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Zhong H; Hansen KB; Boyle NJ; Han K; Muske G; Huang X; Egebjerg J; Sánchez C Neurosci Lett; 2009 Oct; 462(3):207-12. PubMed ID: 19616061 [TBL] [Abstract][Full Text] [Related]
20. [Higher probability of remission with escitalopram in comparison to citalopram]. Linné AB; Hallberg I Lakartidningen; 2009 Apr 28-May 12; 106(18-19):1292; discussion 1292-3. PubMed ID: 19537504 [No Abstract] [Full Text] [Related] [Next] [New Search]